Esperion Therapeutics, Inc.
NASDAQ:ESPRBiotechnology
+$0.00 today
- Market cap
- $661.15M
- Beta
- 1.07
- P/E (TTM)
- -107.3
- EPS (TTM)
- -$0.03
Volume 0.00M
Average 12.29M
ESPR Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Esperion Therapeutics, Inc.NASDAQ: ESPR
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $2.5M rose 1.5% year over year, ahead of the -11.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 4.8% from the prior quarter. Over 3 fiscal years it compounded at -13.4% a year.
Context
- Stock-based compensation amounted to 2.4% of revenue in FY2025, down 1.2 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1.5% holds above the trailing-twelve-month pace of -11.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 9.87M USD
- Year-over-year change
- -17.7%
- 4-year CAGR
- -20.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.87M | -17.7% |
| FY2024 | 2024-12-31 | 11.99M | +0.3% |
| FY2023 | 2023-12-31 | 11.96M | -21.4% |
| FY2022 | 2022-12-31 | 15.22M | -37.4% |
| FY2021 | 2021-12-31 | 24.31M | — |
Stock-Based Compensation vs competitors
How ESPR compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -11.7% is the 8th highest of 10, against a peer median of +3.6%.
- Stock-based compensation amounts to 2.4% of revenue for ESPR, versus a peer median of 5.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $42.3M USD | +40.4% | +15.9% | 5.1% | |
| LTM Mar 2026 | $34.64M USD | -7.4% | -5.4% | 39.4% | |
| LTM Mar 2026 | $16.6M USD | +22.1% | -28.9% | 2.5% | |
| LTM Mar 2026 | $13.53M USD | -11.4% | +13.5% | 737.0% | |
| LTM Mar 2026 | $13.21M USD | -40.1% | — | — | |
| LTM Mar 2026 | CA$13.13M CAD | -20.8% | +12.9% | 1.4% | |
| LTM Mar 2026 | $9.91M USD | -11.7% | -13.4% | 2.4% | |
| LTM Mar 2026 | $8.36M USD | +17.6% | +20.3% | 16.6% | |
| LTM Mar 2026 | $6.73M USD | +88.8% | +25.6% | — | |
| LTM Mar 2026 | $3.53M USD | +3.6% | +27.4% | 3.8% | |
| Peer median (excluding ESPR) | — | +3.6% | +14.7% | 5.1% | |
Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (269.11M) | (233.66M) | (209.25M) | (51.75M) | (22.68M) |
| Depreciation & Amortization | 612K | 500K | 164K | 63K | 105K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 24.31M | 15.22M | 11.96M | 11.99M | 9.87M |
| Change in Working Capital | (52.51M) | (3.37M) | 13.68M | (60.53M) | (14.64M) |
| Accounts Receivables | (10.55M) | (10.8M) | (14.77M) | (31.65M) | (60.05M) |
| Inventory | (18.26M) | (807K) | (30.42M) | (28.87M) | (10.63M) |
| Accounts Payables | (34.1M) | 5.6M | 8.68M | 12.43M | 20.92M |
| Other Working Capital | 10.39M | 2.63M | 50.18M | (12.45M) | 35.12M |
| Other Non-Cash Items | 32.89M | 46.49M | 47.96M | 76.57M | 14.26M |
| Operating Cash Flow | (263.81M) | (174.83M) | (135.49M) | (23.65M) | (13.09M) |
| Capital Expenditures | 0 | 0 | 0 | (317K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (50.48M) | (59.9M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 68M | 42.5M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (50.48M) | 8.1M | 42.5M | (317K) | 0 |
| Debt Repayment | (440K) | (58.24M) | (15.51M) | 35.01M | (54.91M) |
| Common Stock Issued | 218.69M | 90.85M | 56.88M | 91.19M | 98.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 49.98M | 0 | (6.42M) | (39.72M) | (7.26M) |
| Financing Cash Flow | 268.22M | 32.61M | 50.46M | 86.48M | 36.18M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (46.07M) | (134.12M) | (42.53M) | 62.51M | 23.09M |
| Free Cash Flow | (263.81M) | (174.83M) | (135.49M) | (23.97M) | (13.09M) |
Esperion Therapeutics, Inc.
NASDAQ:ESPR
Intrinsic Alpha fair value
Locked
Current Price
$3.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.